For French animal vaccine producer Ceva-Phylaxia, cryogenics technology plays a significant role in its day-to-day business. The company produces live, as well as inactivated, viral and bacterial vaccines across its 13 R&D centres and 23 production sites in 44 countries around the globe, which need to be frozen in controlled conditions and stored in liquid nitrogen.
One of the fastest growing top 10 animal healthcare companies, Ceva-Phylaxia estimates a staggering 75% of all emerging human infectious diseases originate from animals and birds. These zoonoses, as they are known, are what compels the company to innovate and succeed in the fight against the likes of avian flu, brucellosis and Q-fever.
Ceva-Phylaxia works with welfare and social programmes around the world to bring its vision – ‘Together, beyond animal health’ – to life. From working with small-scale livestock owners and vets in Uganda, to supplying the biggest animal welfare charities in the UK and US with special calming collars to help rehome shelter dogs, Ceva-Phylaxia is a truly global company.
... to continue reading you must be subscribed
